EXAS director sells 1,485 shares at $42.02 under 10b5-1 plan

James Edward Doyle, a director of Exact Sciences Corporation (EXAS), reported a sale of company common stock.

Rhea-AI Filing Summary

James Edward Doyle, a director of Exact Sciences Corporation (EXAS), reported a sale of company common stock. The Form 4 shows a disposition of 1,485 shares on 08/13/2025 at a reported price of $42.02 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the sale, the filing reports 59,962 shares beneficially owned by Mr. Doyle. The Form 4 was signed via power of attorney on 08/14/2025.

Insights

Securities Analyst

TL;DR: Insider sale under a pre-existing 10b5-1 plan; routine disclosure with limited immediate market implication.

The recorded transaction is a non-derivative disposition of 1,485 shares executed under a Rule 10b5-1 trading plan, which indicates the sale was pre-planned and not an ad hoc trade. The amount sold (1,485 shares) represents a small fraction of the total reported post-transaction holding (59,962 shares), suggesting this is not a materially dilutive or strategic change in ownership. The filing includes the required power of attorney signature, completing the disclosure obligations.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16 timing and Rule 10b5-1 notice; governance procedures appear followed.

The director checked the box indicating the trade was made pursuant to a 10b5-1 plan and provided the plan execution date. The Form 4 was executed by an attorney-in-fact and includes Exhibit 24 reference for power of attorney. From a governance perspective, the filing contains the expected information for an insider sale and does not state any amendments or additional relationships beyond direct ownership.

Insider Trade Summary

Net Seller: 1,485 shares

Net Sell 1 txn

Insider Doyle James Edward

Role Director

Sold 1,485 shs ($62K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,485	$42.02	$62K

Holdings After Transaction: Common Stock — 59,962 shares (Direct)

Footnotes (1)

1. F1. The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EXAS director James Edward Doyle report on Form 4?

The Form 4 reports a sale of 1,485 shares of Exact Sciences common stock on 08/13/2025 at $42.02 per share.

Was the sale by EXAS director James Edward Doyle part of a 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan entered into on 03/09/2025.

How many EXAS shares did James Edward Doyle beneficially own after the reported transaction?

The Form 4 reports 59,962 shares beneficially owned following the reported sale.

When was the Form 4 for James Edward Doyle signed and by whom?

The Form 4 shows a signature by attorney-in-fact Mark Busch on behalf of James Edward Doyle dated 08/14/2025, and references Exhibit 24 (Power of Attorney).

Does the Form 4 indicate any amendments or additional transactions?

No amendment date is provided in the filing; the Form 4 does not list additional transactions beyond the reported sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle James Edward

(Last) (First) (Middle)

EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WI 53719

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		S		1,485(1)	D	$42.02	59,962	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Edward Doyle by Mark Busch, attorney-in- fact	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.